<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402337</url>
  </required_header>
  <id_info>
    <org_study_id>MCP-103-201</org_study_id>
    <nct_id>NCT00402337</nct_id>
  </id_info>
  <brief_title>Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation</brief_title>
  <official_title>A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-group, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy and safety of administration of
      linaclotide acetate in patients with chronic constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Pretreatment in Weekly Normalized Spontaneous Bowel Movement (SBM) Frequency</measure>
    <time_frame>Change from Baseline to Week 4</time_frame>
    <description>Change in SBM frequency during Weeks 1 through 4 of the treatment period from the weekly SBM rate obtained during the pretreatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</measure>
    <time_frame>Change from Baseline to Week 4</time_frame>
    <description>A patient was an SBM 75% Responder if the patient was an SBM Responder for ≥3 of the 4 treatment period weeks.
For each week of the treatment and postreatment periods, a patient was considered an SBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had an SBM rate of ≥ 3 for the week, and 3) had an increase in SBM rate of ≥ 1 from their baseline weekly SBM rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</measure>
    <time_frame>Change from Baseline to Week 4</time_frame>
    <description>A patient was a complete spontaneous bowel movement (CSBM) 75% Responder if the patient was a CSBM Responder for ≥3 of the 4 treatment period weeks.
For each week of the treatment and postreatment periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from their baseline weekly CSBM rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Weekly Normalized CSBM Rate for the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 4</time_frame>
    <description>CSBMs measured daily during the treatment period. During each daily phone call into the IVRS, patients were asked: How many bowel movements did you have today or yesterday after your last call?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Stool Consistency (BSFS) Score for the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 4</time_frame>
    <description>Stool consistency analyses were performed using the 7-point BSFS, whereby a score of 1 = difficult to pass; 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = entirely liquid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Straining Score for the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 4</time_frame>
    <description>Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Chronic Constipation</condition>
  <arm_group>
    <arm_group_label>72 ug linaclotide acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>145 ug linaclotide acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>290 ug linaclotide acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>579 ug linaclotide acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linaclotide acetate</intervention_name>
    <description>oral, once daily.</description>
    <arm_group_label>72 ug linaclotide acetate</arm_group_label>
    <arm_group_label>145 ug linaclotide acetate</arm_group_label>
    <arm_group_label>290 ug linaclotide acetate</arm_group_label>
    <arm_group_label>579 ug linaclotide acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>oral, once daily</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 18 years of age or older

          -  Patient meets colonoscopy requirements according to the American Gastroenterological
             Association

          -  Patient meets criteria for chronic constipation including weekly bowel movement
             frequency requirements and reports one or more symptoms of constipation according to
             protocol requirements

          -  Patient has successfully completed study requirements with no clinically-significant
             findings: physical exam, ECG, clinical laboratory tests

          -  Patient is fluent in English

        Exclusion Criteria:

          -  Patient reports loose or watery stools

          -  Patient meets criteria for IBS including protocol-defined abdominal discomfort or pain

          -  Patient may not take prohibited medications per protocol

          -  Medical diagnoses, medical conditions, or family history that would not make the
             patient a good candidate for the study or limit the patient's ability to complete the
             clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Microbia Medical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Microbia, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Arkansas</state>
        <zip>72120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Pittsford</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>9199668328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>September 28, 2012</results_first_submitted>
  <results_first_submitted_qc>January 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2013</results_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Constipation</keyword>
  <keyword>Chronic Constipation</keyword>
  <keyword>Microbia</keyword>
  <keyword>linaclotide</keyword>
  <keyword>linaclotide acetate</keyword>
  <keyword>MD-1100</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment occurred over a 13 month period from November 2006 to December 2007 at 57 US study sites.</recruitment_details>
      <pre_assignment_details>Patients went through a 14 to 17 day Pretreatment Period during which the patients provided qualifying bowel habit and symptoms, and rescue medicine usage information through an interactive voice response system (IVRS).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Linaclotide, 72μg</title>
          <description>Linaclotide, 72μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P2">
          <title>Linaclotide, 145μg</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P3">
          <title>Linaclotide, 290μg</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P4">
          <title>Linaclotide, 579μg</title>
          <description>Linaclotide, 579μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Dose-matched placebo, oral administration, once per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linaclotide, 72μg</title>
          <description>Linaclotide, 72μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B2">
          <title>Linaclotide, 145μg</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day. One patient was randomized into the study but did not receive ≥ 1 dose of study drug, thus was not included in the Safety Population.</description>
        </group>
        <group group_id="B3">
          <title>Linaclotide, 290μg</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B4">
          <title>Linaclotide, 579μg</title>
          <description>Linaclotide, 579μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Dose-matched placebo, oral administration, once per day.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="309"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="14.1"/>
                    <measurement group_id="B2" value="46.4" spread="11.7"/>
                    <measurement group_id="B3" value="48.4" spread="12.7"/>
                    <measurement group_id="B4" value="49.2" spread="14.0"/>
                    <measurement group_id="B5" value="46.1" spread="15.5"/>
                    <measurement group_id="B6" value="47.2" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 years to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Older than 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Pretreatment in Weekly Normalized Spontaneous Bowel Movement (SBM) Frequency</title>
        <description>Change in SBM frequency during Weeks 1 through 4 of the treatment period from the weekly SBM rate obtained during the pretreatment period.</description>
        <time_frame>Change from Baseline to Week 4</time_frame>
        <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 “How many bowel movements did you have today or yesterday since your last call?” were included in the intent-to-treat (ITT) Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 72μg</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>Linaclotide, 579μg</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pretreatment in Weekly Normalized Spontaneous Bowel Movement (SBM) Frequency</title>
          <description>Change in SBM frequency during Weeks 1 through 4 of the treatment period from the weekly SBM rate obtained during the pretreatment period.</description>
          <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 “How many bowel movements did you have today or yesterday since your last call?” were included in the intent-to-treat (ITT) Population.</population>
          <units>SBMs per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="0.407"/>
                    <measurement group_id="O2" value="3.25" spread="0.412"/>
                    <measurement group_id="O3" value="3.57" spread="0.391"/>
                    <measurement group_id="O4" value="4.29" spread="0.394"/>
                    <measurement group_id="O5" value="1.45" spread="0.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the active treatment group is equal to the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0337</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the active treatment group is equal to the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the active treatment group is equal to the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the active treatment group is equal to the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</title>
        <description>A patient was an SBM 75% Responder if the patient was an SBM Responder for ≥3 of the 4 treatment period weeks.
For each week of the treatment and postreatment periods, a patient was considered an SBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had an SBM rate of ≥ 3 for the week, and 3) had an increase in SBM rate of ≥ 1 from their baseline weekly SBM rate.</description>
        <time_frame>Change from Baseline to Week 4</time_frame>
        <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 72μg</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>Linaclotide, 579μg</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>SBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</title>
          <description>A patient was an SBM 75% Responder if the patient was an SBM Responder for ≥3 of the 4 treatment period weeks.
For each week of the treatment and postreatment periods, a patient was considered an SBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had an SBM rate of ≥ 3 for the week, and 3) had an increase in SBM rate of ≥ 1 from their baseline weekly SBM rate.</description>
          <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</title>
        <description>A patient was a complete spontaneous bowel movement (CSBM) 75% Responder if the patient was a CSBM Responder for ≥3 of the 4 treatment period weeks.
For each week of the treatment and postreatment periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from their baseline weekly CSBM rate.</description>
        <time_frame>Change from Baseline to Week 4</time_frame>
        <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 72μg</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>Linaclotide, 579μg</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</title>
          <description>A patient was a complete spontaneous bowel movement (CSBM) 75% Responder if the patient was a CSBM Responder for ≥3 of the 4 treatment period weeks.
For each week of the treatment and postreatment periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from their baseline weekly CSBM rate.</description>
          <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Weekly Normalized CSBM Rate for the Treatment Period</title>
        <description>CSBMs measured daily during the treatment period. During each daily phone call into the IVRS, patients were asked: How many bowel movements did you have today or yesterday after your last call?</description>
        <time_frame>Change from Baseline to Week 4</time_frame>
        <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 72μg</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>Linaclotide, 579μg</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Weekly Normalized CSBM Rate for the Treatment Period</title>
          <description>CSBMs measured daily during the treatment period. During each daily phone call into the IVRS, patients were asked: How many bowel movements did you have today or yesterday after your last call?</description>
          <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT Population.</population>
          <units>CSBMs per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.295"/>
                    <measurement group_id="O2" value="1.59" spread="0.298"/>
                    <measurement group_id="O3" value="1.75" spread="0.283"/>
                    <measurement group_id="O4" value="2.26" spread="0.285"/>
                    <measurement group_id="O5" value="0.45" spread="0.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Stool Consistency (BSFS) Score for the Treatment Period</title>
        <description>Stool consistency analyses were performed using the 7-point BSFS, whereby a score of 1 = difficult to pass; 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = entirely liquid.</description>
        <time_frame>Change from Baseline to Week 4</time_frame>
        <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT. 29 patients with no pretreatment spontaneous bowel movements were excluded from the Stool Consistency analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 72μg</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>Linaclotide, 579μg</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Stool Consistency (BSFS) Score for the Treatment Period</title>
          <description>Stool consistency analyses were performed using the 7-point BSFS, whereby a score of 1 = difficult to pass; 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = entirely liquid.</description>
          <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT. 29 patients with no pretreatment spontaneous bowel movements were excluded from the Stool Consistency analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.182"/>
                    <measurement group_id="O2" value="1.57" spread="0.177"/>
                    <measurement group_id="O3" value="1.68" spread="0.175"/>
                    <measurement group_id="O4" value="2.00" spread="0.171"/>
                    <measurement group_id="O5" value="0.50" spread="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Straining Score for the Treatment Period</title>
        <description>Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.</description>
        <time_frame>Change from Baseline to Week 4</time_frame>
        <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT Population. 29 patients with no pretreatment spontaneous bowel movements were excluded from the Straining analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 72μg</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>Linaclotide, 579μg</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Straining Score for the Treatment Period</title>
          <description>Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.</description>
          <population>307 patients who received ≥ 1 capsule of study drug and had ≥ 1 post-baseline response to the IVRS Treatment Period Question #12 &quot;How many bowel movements did you have today or yesterday since your last call?&quot; were included in the ITT Population. 29 patients with no pretreatment spontaneous bowel movements were excluded from the Straining analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.102"/>
                    <measurement group_id="O2" value="-0.97" spread="0.098"/>
                    <measurement group_id="O3" value="-1.11" spread="0.097"/>
                    <measurement group_id="O4" value="-1.14" spread="0.095"/>
                    <measurement group_id="O5" value="-0.52" spread="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from November of 2006 to February of 2008.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linaclotide, 72μg</title>
          <description>Linaclotide, 72μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E2">
          <title>Linaclotide, 145μg</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E3">
          <title>Linaclotide, 290μg</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E4">
          <title>Linaclotide, 579μg</title>
          <description>Linaclotide, 579μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Dose-matched placebo, oral administration, once per day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI is that publication cannot be made for 24 months from the date of final data lock of the study, the sponsor can review the publication prior to public release, sponsor requires a minimum 60 day review period for each publication, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request an additional delay period of 60 days in order to protect potentially patentable information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Doug Levine, MD</name_or_title>
      <organization>Ironwood Pharmaceuticals</organization>
      <phone>617.374.3906</phone>
      <email>dlevine@ironwoodpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

